Compare LYEL & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYEL | GLRE |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 481.5M |
| IPO Year | 2021 | 2007 |
| Metric | LYEL | GLRE |
|---|---|---|
| Price | $22.29 | $14.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 94.8K | 80.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.74 |
| Revenue | $61,000.00 | ★ $696,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.27 |
| Revenue Growth | N/A | ★ 4.34 |
| 52 Week Low | $0.39 | $11.57 |
| 52 Week High | $45.00 | $15.06 |
| Indicator | LYEL | GLRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 51.21 |
| Support Level | $21.27 | $12.49 |
| Resistance Level | $27.30 | $14.60 |
| Average True Range (ATR) | 2.05 | 0.29 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 29.36 | 47.52 |
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.